---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093888"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:10:52.251516+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioAtla Q2 net loss $21.1M; cash to Q3 2025; Fast Track for ozuriftamab vedotin

## Summary
- Net loss of $21.1M for Q2 2024 vs $35.8M in Q2 2023; R&D expenses fell to $16.2M from $31.0M.
- Cash and equivalents $61.7M as of June 30, 2024, expected to fund operations through Q3 2025.
- Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track by FDA for SCCHN; FDA meeting for registrational trial expected in 2H 2024.
- Mecbotamab vedotin (CAB-AXL-ADC) Phase 2 in NSCLC shows OS trend in mutated KRAS; responses across G12A, G12C, G12V.
- Evalstotug (CAB-CTLA-4) combined Phase 1/2 safety: low grade 3 irAEs (4/40); Phase 2 melanoma data on track for 2H 2024.

## SEC filing metadata
- accession: 0000950170-24-093888
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000095017024093888/0000950170-24-093888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000095017024093888/bcab-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093888
- JSON: https://secwatch.observer/filing/0000950170-24-093888.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093888.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.